Drugs / Antiscorpion venom serum
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00753064 Comparator | Sep 2006 → Dec 2007 | scorpion envenomation | Haffkine Bio-Pharmaceutical Corporation Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antiscorpion venom serum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753064 ↗ |
| Known as | AScVS | “Antiscorpion venom serum(AScVS).” NCT00753064 ↗ |
| Modality | Protein / enzyme biologic | “enzyme refined AScVS ( Monovalent Anti-scorpion venom serum against Mesobuthus tamulus concanesis Pocock.)” NCT00753064 ↗ |
| Route | Intravenous | “Computed doses were given according to clinical grading as intravenous bolus slowly.” NCT00753064 ↗ |